Table 2.

Ongoing clinical trials evaluating PI3Kα inhibitors in cancer, including patients with head and neck cancer.

PI3Kα inhibitor	Other interventions	Conditions	PI3K Biomarker	Phase	Status	Clinical trial identifier
Alpelisib		Advanced solid tumors	PIK3CA mutation	I	Active, not recruiting	NCT01219699
Buparlisib	Gefitinib	Non-small cell lung cancer (NSCLC), enriched with solid tumors	Hyperactive PI3K pathway, historic EGFR mutation	I	Active, not recruiting	NCT01570296
Copanlisib	Nivolumab	Metastatic solid tumors, lymphomas	None	I	Recruiting	NCT03502733
Copanlisib		Solid tumors, lymphomas	None	I/II	Recruiting	NCT03458728
Copanlisib	Olaparib, durvalumab	Metastatic or unresectable solid tumors	None	I	Recruiting	NCT03842228
Copanlisib	Nivolumab	Metastatic or unresectable microsatellite stable (MSS) solid tumors, MSS colon cancer	None	I/II	Recruiting	NCT03711058
Copanlisib, GSK2636771, Taselisib		Refractory solid tumors, lymphomas, multiple myeloma	PIK3CA mutation or PTEN mutation/loss (copanlisib), PTEN mutation/loss (GSK2636771), PIK3CA mutations without RAS mutation or PTEN loss (taselisib)	II	Recruiting	NCT02465060
Gedatolisib	Palbociclib	Head and neck, lung, pancreatic, other solid tumors	None	I	Recruiting	NCT03065062